Abstract
This study was designed to explore the anticancer potential of isoalantolactone, a sesquiterpene lactone, on esophageal squamous cell carcinoma (ESCC) cells and associated molecular mechanisms. ESCC cell lines were treated with isoalantolactone or vehicle and tested for viability, proliferation, cell cycle distribution, and apoptosis. Xenograft tumor studies in nude mice were done to examine the in vivo anticancer effect of isoalantolactone. Isoalantolactone treatment reduced ESCC cell viability and proliferation in vitro, which was coupled with induction of G0/G1 cell cycle arrest and apoptosis. In vivo studies confirmed the growth-suppressive effect of isoalantolactone on ESCC cells. Mechanistically, isoalantolactone reversed microRNA-21-mediated repression of programmed cell death 4 (PDCD4). Overexpression of microRNA-21 and knockdown of PDCD4 blocked the growth suppression and apoptosis induction by isoalantolactone in ESCC cells. Isoalantolactone shows growth-suppressive activity against ESCC cells, which is ascribed to upregulation of PDCD4 via downregulation of microRNA-21.
References
Aug 31, 2004·Oncogene·Nadja BitomskyKarl-Heinz Klempnauer
Mar 12, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yukiharu HiyoshiHideo Baba
Mar 26, 2009·Cancer Research·Masaki ShiotaKimitoshi Kohno
Nov 19, 2011·FEMS Microbiology Letters·Jiazhang QiuXuming Deng
Apr 26, 2012·International Journal of Biological Sciences·Muhammad KhanTonghui Ma
Jul 25, 2013·Archives of Pharmacal Research·Azhar RasulTonghui Ma
Oct 8, 2013·PloS One·Minjun WuLihua Li
Aug 12, 2014·Oncology Reports·Weihua DiTonghui Ma
Jul 20, 2016·International Journal of Molecular Medicine·Yang LiZhengang Cai
Aug 18, 2016·Molecular Carcinogenesis·Xu-Hua MaoZei-Yong Xu
Sep 8, 2016·Archives of Pharmacal Research·Ziliang LiDan Wu
Sep 17, 2016·Oncotarget·Kai YinWenxian Guan
Oct 26, 2016·Oncology Reports·Bo YangHuajun Zhao
Nov 24, 2016·Scientific Reports·Poyil PratheeshkumarXianglin Shi
Dec 4, 2016·Molecular Cancer Therapeutics·Shuo WangAntonis E Koromilas
Dec 28, 2016·Cancer Letters·Rashmi BhartiMahitosh Mandal
Feb 10, 2017·Scientific Reports·Mingyue LiClara Bik-San Lau
Mar 4, 2017·Scientific Reports·Guanghui XuHongwei Zhang
Apr 14, 2017·PloS One·Feng WangQingxia Fan
Apr 14, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Guodong HeYubo Xie
Citations
Sep 22, 2019·International Journal of Molecular Sciences·Michaela ŠadibolováIva Boušová
Oct 18, 2019·Frontiers in Oncology·Mengxiang ZhaoLiang Ding
Mar 9, 2021·Biochemical Pharmacology·Hui WengDongliang Wang
Mar 14, 2021·Thoracic Cancer·Demiao KongMeng Luo
Sep 6, 2020·Developmental and Comparative Immunology·Xiaoli GaoShuangbao Gun